Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 95

Sort by

Sort Order Select

Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood (2024) 144 (18): 1951–1961.

https://doi.org/10.1182/blood.2024024761

Published: 2024

Includes: Supplemental data

Journal Articles

Cytoreductive Chemotherapy in Induction Therapy Plays a Key Role in the Prognosis of Patients with Low-Risk Acute Promyelocytic Leukemia

Xiaolu Zhu, Feifei Tang, Wenjing Yu, Xiaosu Zhao, Yazhen Qin, Qian Jiang, Xiao Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 1481.

https://doi.org/10.1182/blood-2023-180002

Published: 2023

Journal Articles

Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results

Blood (2023) 142 (Supplement 1): 5954.

https://doi.org/10.1182/blood-2023-184959

Published: 2023

Journal Articles

Olverembatinib (HQP1351) Combined with Chemotherapy Is an Effective and Safe Treatment in Patients with Philadelphia Chromosome-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CML-LBP) That Failed TKI-Based Regimens

Zongru Li, Zhao Ting, Lijuan Hu, Wenbing Duan, Qian Jiang

Blood (2023) 142 (Supplement 1): 5895.

https://doi.org/10.1182/blood-2023-185471

Published: 2023

Journal Articles

Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 2925.

https://doi.org/10.1182/blood-2023-188489

Published: 2023

Journal Articles

Blood Basophil Concentration at Diagnosis Corelates with Prognosis in Newly-Diagnosed Persons with Chronic Myeloid Leukaemia

Lucia Vrablova, Xiaoshuai Zhang, Eva Kriegova, Milos Kudelka, Martin Radvansky, Sen Yang, Jaroslava Juranova, Tomas Papajik, Robert Peter Gale, Qian Jiang, Edgar Faber

Blood (2023) 142 (Supplement 1): 6374.

https://doi.org/10.1182/blood-2023-187548

Published: 2023

Journal Articles

3rd-Generation Tyrosine Kinase-Inhibitors and Azacitidine Are Safe and Effective in Myeloid Blast-Phase Chronic Myeloid Leukaemia and Result in a High Proportion of Subjects in 2 nd Chronic Phase Able to Receive a Transplant

Mei Bao, Xiang Wang, Xiao-shuai Zhang, Zong-ru Li, Robert Peter Gale, Xiao-jun Huang, Qian Jiang

Blood (2023) 142 (Supplement 1): 4550.

https://doi.org/10.1182/blood-2023-185346

Published: 2023

Journal Articles

Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival

Wenbing Duan, Jinsong Jia, Jing Wang, Xiaohong Liu, Lizhong Gong, WenJing Yu, Xiaolu Zhu, Zhao Ting, Qian Jiang, Guorui Ruan, Xiaosu Zhao, Yu Wang, Hongxia Shi, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 4309.

https://doi.org/10.1182/blood-2023-184769

Published: 2023

Journal Articles

Tgrx-678, a Novel Allosteric Inhibitor of BCR-ABL1, Demonstrates Preclinical Anti-Leukemia Activity, High Oral Bioavailability and Synergism with Ponatinib to Suppress the Highly Resistant Compound Mutations

Yanxia Shi, Qian Jiang, Linxin Li, Shuzhen Jiang, Tingting Yan, Cuifang Zheng, Yixin Ai, Yihan Wang

Blood (2023) 142 (Supplement 1): 2807.

https://doi.org/10.1182/blood-2023-181391

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQOL) in Patients (Pts) with Tyrosine Kinase Inhibitor- (TKI)-Resistant Chronic Myeloid Leukemia (CML) Receiving Olverembatinib (HQP1351) Therapy

Lu Yu, Lichuang Men, Zongru Li, Xiaojun Huang, Qian Jiang

Blood (2023) 142 (Supplement 1): 6358.

https://doi.org/10.1182/blood-2023-188406

Published: 2023

Journal Articles

A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia

Xiao-shuai Zhang, Bingcheng Liu, Jian Huang, Xin Du, Yanli Zhang, Na Xu, Xiaoli Liu, Li Weiming, Hai Lin, Huanling Zhu, Yunfan Yang, Ling Pan, Xiao-jun Huang, Qian Jiang

Blood (2023) 142 (Supplement 1): 3167.

https://doi.org/10.1182/blood-2023-185473

Published: 2023

Journal Articles

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Feifei Tang, Wen-Bing Duan, Xiao-Hong Liu, Sheng-Ye Lu, Xiao-Su Zhao, Ya-Zhen Qin, Jin-Song Jia, Jing Wang, Li-Zhong Gong, Qian Jiang, Zhao Ting, Hong-Xia Shi, Ying-Jun Chang, Xiao-Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2023-188657

Published: 2023

Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Blood (2023) 142 (Supplement 1): 869.

https://doi.org/10.1182/blood-2023-187740

Published: 2023

Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

Qian Jiang, Yanli Zhang, Qiang Wang, Jianyu Weng, Zhenfang Liu, Suning Chen, Li Weiming, Bingcheng Liu, Zhuogang Liu, Yihan Wang, Jingrong Cao

Blood (2023) 142 (Supplement 1): 867.

https://doi.org/10.1182/blood-2023-185977

Published: 2023

Journal Articles

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Blood (2023) 142 (Supplement 1): 1814.

https://doi.org/10.1182/blood-2023-179043

Published: 2023

Journal Articles

Is the Prognosis of People with Chronic Myeloid Leukaemia Presenting in Accelerated Phase Always Worse Compared with People Presenting in Chronic Phase?

Sen Yang, Xiaoshuai Zhang, Mengyu Zhang, Robert Peter Gale, Xiao Jun Huang, Qian Jiang

Blood (2023) 142 (Supplement 1): 1804.

https://doi.org/10.1182/blood-2023-184568

Published: 2023

Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Blood (2022) 140 (Supplement 1): 203–204.

https://doi.org/10.1182/blood-2022-170698

Published: 2022

Journal Articles

A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China

Qian Jiang, Zongru Li, Ya-Zhen Qin, Ting Zhao, Bingcheng Liu, Zi Chen, Qian Niu, Lichuang Men, Hengbang Wang, Dajun Yang, Yifan Zhai, Xiao-Jun Huang

Blood (2022) 140 (Supplement 1): 198–199.

https://doi.org/10.1182/blood-2022-170868

Published: 2022

Journal Articles

Outcome and Molecular Measurable Residual Disease Monitoring in Adult B-Cell Acute Lymphoblastic Leukemia Patients with MEF2D Fusions

Kai Sun, Wen-Min Chen, Xu Wang, Xiao-Su Zhao, Ling-Di Li, Yue Hao, Jun Wang, Nan Xu, Hao Jiang, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Qian Jiang, Xiao Jun Huang, Ya-Zhen Qin

Blood (2022) 140 (Supplement 1): 11864–11865.

https://doi.org/10.1182/blood-2022-159866

Published: 2022

Journal Articles

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Blood (2022) 140 (Supplement 1): 815–817.

https://doi.org/10.1182/blood-2022-166855

Published: 2022

NARROW

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Cytoreductive Chemotherapy in Induction Therapy Plays a Key Role in the Prognosis of Patients with Low-Risk Acute Promyelocytic Leukemia

Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results

Olverembatinib (HQP1351) Combined with Chemotherapy Is an Effective and Safe Treatment in Patients with Philadelphia Chromosome-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CML-LBP) That Failed TKI-Based Regimens

Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms

Blood Basophil Concentration at Diagnosis Corelates with Prognosis in Newly-Diagnosed Persons with Chronic Myeloid Leukaemia

3rd-Generation Tyrosine Kinase-Inhibitors and Azacitidine Are Safe and Effective in Myeloid Blast-Phase Chronic Myeloid Leukaemia and Result in a High Proportion of Subjects in 2 nd Chronic Phase Able to Receive a Transplant

Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival

Tgrx-678, a Novel Allosteric Inhibitor of BCR-ABL1, Demonstrates Preclinical Anti-Leukemia Activity, High Oral Bioavailability and Synergism with Ponatinib to Suppress the Highly Resistant Compound Mutations

Health-Related Quality of Life (HRQOL) in Patients (Pts) with Tyrosine Kinase Inhibitor- (TKI)-Resistant Chronic Myeloid Leukemia (CML) Receiving Olverembatinib (HQP1351) Therapy

A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Is the Prognosis of People with Chronic Myeloid Leukaemia Presenting in Accelerated Phase Always Worse Compared with People Presenting in Chronic Phase?

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China

Outcome and Molecular Measurable Residual Disease Monitoring in Adult B-Cell Acute Lymphoblastic Leukemia Patients with MEF2D Fusions

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only